These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34257489)

  • 1. The Characteristics and Outcomes of Patients with Heart Failure and Reduced Ejection Fraction: The Eligibility of Novel Heart Failure Medications.
    Fong MC; Chang HY; Wang CC; Feng AN; Lin WS; Wu YW; Sung SH; Huang JL; Kuo JY; Yin WH
    Acta Cardiol Sin; 2021 Jul; 37(4):394-403. PubMed ID: 34257489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.
    Kapelios CJ; Lainscak M; Savarese G; Laroche C; Seferovic P; Ruschitzka F; Coats A; Anker SD; Crespo-Leiro MG; Filippatos G; Piepoli MF; Rosano G; Zanolla L; Aguiar C; Murin J; Leszek P; McDonagh T; Maggioni AP; Lund LH;
    Eur J Heart Fail; 2019 Nov; 21(11):1383-1397. PubMed ID: 31132222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with angiotensin receptor neprilysin inhibitor for Taiwan heart failure patients: Rationale and baseline characteristics of the TAROT-HF study.
    Lin WY; Chung FP; Liao CT; Huang JL; Liang HW; Lee YH; Lin PL; Chiou WR; Hsu CY; Chang HY
    J Chin Med Assoc; 2021 Sep; 84(9):833-841. PubMed ID: 34524212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting.
    Nordberg Backelin C; Fu M; Ljungman C
    ESC Heart Fail; 2020 Jun; 7(3):1049-1055. PubMed ID: 32030899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study.
    Houchen E; Loefroth E; Schlienger R; Proudfoot C; Corda S; Saha S; Satwase SK; Studer R
    Cardiol Ther; 2022 Mar; 11(1):113-127. PubMed ID: 35094306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of sacubitril/valsartan in patients with heart failure in primary care in Germany: the AURORA-HF noninterventional study.
    Zeymer U; Groves R; Hupfer S
    Herz; 2024 Apr; ():. PubMed ID: 38656397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients.
    Liao CT; Huang JL; Liang HW; Chung FP; Lee YH; Lin PL; Chiou WR; Lin WY; Hsu CY; Chang HY
    ESC Heart Fail; 2021 Oct; 8(5):4199-4210. PubMed ID: 34327853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Blocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure Registry.
    Eriksen-Volnes T; Westheim A; Gullestad L; Slind EK; Grundtvig M
    Biomed Hub; 2020; 5(1):9-18. PubMed ID: 32775329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.
    Torrado J; Cain C; Mauro AG; Romeo F; Ockaili R; Chau VQ; Nestler JA; Devarakonda T; Ghosh S; Das A; Salloum FN
    J Am Coll Cardiol; 2018 Nov; 72(19):2342-2356. PubMed ID: 30384891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
    Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
    Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
    Fudim M; Sayeed S; Xu H; Matsouaka RA; Heidenreich PA; Velazquez EJ; Yancy CW; Fonarow GC; Hernandez AF; DeVore AD
    Circ Heart Fail; 2020 Apr; 13(4):e006645. PubMed ID: 32248695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
    Nguyen E; Weeda ER; White CM
    J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta-analysis of randomized controlled trials.
    Bryan Richard S; Huang B; Liu G; Yang Y; Luo S
    Clin Cardiol; 2021 Apr; 44(4):463-471. PubMed ID: 33638556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
    Brunner-La Rocca HP; Linssen GC; Smeele FJ; van Drimmelen AA; Schaafsma HJ; Westendorp PH; Rademaker PC; van de Kamp HJ; Hoes AW; Brugts JJ;
    JACC Heart Fail; 2019 Jan; 7(1):13-21. PubMed ID: 30606482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
    Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study.
    Armentaro G; D'Arrigo G; Miceli S; Cassano V; Perticone M; Maio R; Marra AM; Arturi F; Cittadini A; Tripepi G; Sesti G; Sciacqua A
    Front Physiol; 2022; 13():897109. PubMed ID: 35694400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up.
    Paolini C; Mugnai G; Dalla Valle C; Volpiana A; Ferraglia A; Frigo AC; Bilato C
    Int J Cardiol Heart Vasc; 2021 Aug; 35():100821. PubMed ID: 34179333
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.